Cardiovascular Disease (Heart Disease)

Cardiovascular disease (CVD) is a group of conditions that involve the heart or blood vessels. This may include angina, heart attack (myocardial infarction), heart failure, cardiomyopathy, valvular heart disease, peripheral artery disease, and arrhythmias.


The causes of cardiovascular disease vary depending on condition, but common culprits include atherosclerosis, smoking, diabetes, obesity, high cholesterol, alcoholism, lack of exercise, unhealthy diet, and many others.

Heart disease is the leading cause of death among Americans and as such treatment options are numerous. While most of the focus is on prevention, other options include medications, surgery, and lifestyle changes.

Many research dollars are being poured into stem cell treatments to try and improve outcomes for heart disease. The focus of this research is on improving heart function (ejection fraction) and creating alternative circulation to the heart as well as all parts of the body.

If you would like to talk with an expert about your specific condition, please fill out the
form below:

  • Wish to explore treating this condition with us?

    Fill out the form below for free information

The most current research regarding stem cells and Cardiovascular Disease is given below:

Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure
Jorge Bartolucci, Fernando J. Verdugo, Paz L. González, Ricardo E. Larrea, JEma Abarzua, Carlos Goset, Pamela Rojo, Ivan Palma, Ruben Lamich, Pablo A. Pedreros, Gloria Valdivia, Valentina M. Lopez, Carolina Nazzal, Francisca Alcayaga-Miranda, Jimena Cuenca, Matthew J. Brobeck, Amit N. Patel, Fernando E. Figueroa, and Maroun Khoury

Abstract: Umbilical cord–derived mesenchymal stem cells (UC-MSC) are easily accessible and expanded in vitro, possess distinct properties, and improve myocardial remodeling and function in experimental models of cardiovascular disease. Although bone marrow–derived mesenchymal stem cells have been previously assessed for their therapeutic potential in individuals with heart failure and reduced ejection fraction, no clinical trial has evaluated intravenous infusion of UC-MSCs in these patients.